{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:41:28Z","timestamp":1761964888049,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T00:00:00Z","timestamp":1497484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1038\/nrcardio.2017.92","type":"journal-article","created":{"date-parts":[[2017,6,15]],"date-time":"2017-06-15T11:33:17Z","timestamp":1497526397000},"page":"445-446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Statin-associated muscle symptoms \u2014 really all in the mind?"],"prefix":"10.1038","volume":"14","author":[{"given":"Robert M.","family":"Stoekenbroek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J. P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,15]]},"reference":[{"key":"BFnrcardio201792_CR1","doi-asserted-by":"publisher","unstructured":"Gupta, A.  et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial \u2014 Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet \n                    http:\/\/dx.doi.org\/10.1016\/S0140-6736(17)31075-9\n                    \n                   (2017).","DOI":"10.1016\/S0140-6736(17)31075-9"},{"key":"BFnrcardio201792_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert, E., Hayem, G., Dejager, S., Yau, C. & B\u00e9gaud, B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2014 the PRIMO Study. Cardiovasc. Drugs Ther. 19, 403\u2013414 (2005).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"BFnrcardio201792_CR3","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins, R.  et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388, 2532\u20132561 (2016).","journal-title":"Lancet"},{"key":"BFnrcardio201792_CR4","doi-asserted-by":"publisher","first-page":"e013255","DOI":"10.1136\/bmjopen-2016-013255","volume":"7","author":"DL Steen","year":"2017","unstructured":"Steen, D. L., Khan, I., Ansell, D., Sanchez, R. J. & Ray, K. K. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. BMJ Open 7, e013255 (2017).","journal-title":"BMJ Open"},{"key":"BFnrcardio201792_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","volume":"6","author":"JD Cohen","year":"2012","unstructured":"Cohen, J. D., Brinton, E. A., Ito, M. K. & Jacobson, T. A. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J. Clin. Lipidol. 6, 208\u2013215 (2012).","journal-title":"J. Clin. Lipidol."},{"key":"BFnrcardio201792_CR6","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","volume":"69","author":"M-C Serban","year":"2017","unstructured":"Serban, M.-C.  et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J. Am. Coll. Cardiol. 69, 1386\u20131395 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrcardio201792_CR7","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen, S. E.  et al. Efficacy and tolerability of evolocumab versus ezetimibe in patients with muscle-related statin intolerance. JAMA 315, 1580 (2016).","journal-title":"JAMA"},{"key":"BFnrcardio201792_CR8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty, P. M.  et al. Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J. Clin. Lipidol. 9, 758\u2013769 (2015).","journal-title":"J. Clin. Lipidol."},{"key":"BFnrcardio201792_CR9","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes, E. S.  et al. Statin-associated muscle symptoms: impact on statin therapy \u2014 European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 36, 1012\u20131022 (2015).","journal-title":"Eur. Heart J."},{"key":"BFnrcardio201792_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10557-017-6723-4","volume":"31","author":"RS Rosenson","year":"2017","unstructured":"Rosenson, R. S.  et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc. Drugs Ther. 31, 179\u2013186 (2017).","journal-title":"Cardiovasc. Drugs Ther."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2017.92.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2017.92","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrcardio.2017.92","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrcardio.2017.92.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:01:43Z","timestamp":1684468903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrcardio.2017.92"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,15]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["BFnrcardio201792"],"URL":"https:\/\/doi.org\/10.1038\/nrcardio.2017.92","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"type":"print","value":"1759-5002"},{"type":"electronic","value":"1759-5010"}],"subject":[],"published":{"date-parts":[[2017,6,15]]},"assertion":[{"value":"15 June 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.J.P.K. has received grants and personal fees from Amgen, Gemphire, Madrigal Pharma, Merck, Sharpe and Dohme, Sanofi\/Regeneron, and The Medicines Company. R.M.S. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}